Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-08-19
2009-10-06
Henley, III, Raymond J (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S546000, C514S640000, C514S679000, C568S303000, C568S306000, C568S335000, C568S336000
Reexamination Certificate
active
07598289
ABSTRACT:
The present invention pertains to certain ketones and reduced ketones and derivatives thereof which, inter alia, inhibit osteoclast survival, formation, and/or activity; and/or inhibit bone resorption, and more particularly to compounds of the formulae and pharmaceutically acceptable salts, amides, esters, and ethers thereof, wherein: Ar1, Ralk, —ORO, and -Q are as defined herein:The present invention also pertains to pharmaceutical compositions comprising such compounds. The compounds inhibit osteoclast survival, formation, and/or activity, and inhibit conditions mediated by osteoclasts and/or characterised by bone resorption, and are useful in the treatment of bone disorders such as osteoporosis, rheumatoid arthritis, cancer associated bone disease, Paget's disease, aseptic loosening of prosthetic implants, and the like; and/or in the treatment of conditions associated with inflammation or activation of the immune system.
REFERENCES:
patent: 4017416 (1977-04-01), Inukai et al.
patent: 5859047 (1999-01-01), Kluender et al.
patent: 2005/0119305 (2005-06-01), Naka et al.
patent: 1 215 203 (2002-06-01), None
patent: 11-80107 (1999-03-01), None
patent: 2001-352978 (2001-12-01), None
patent: WO 97/10247 (1997-03-01), None
patent: WO 97/41099 (1997-11-01), None
patent: WO 02/074298 (2002-09-01), None
patent: WO 02/092588 (2002-11-01), None
patent: WO 03/037321 (2003-05-01), None
Baud, V. et al, 1999, “Signaling by proinflammatory cytokines: oligomerization of TRAF2 and TRAF6 is sufficient for JNK and IKK activation and target gene induction via an amino-terminal effector domain”,Genes Dev., vol. 13, pp. 1297-1308.
Brennan, F.M. et al, 1989, “Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis”,Lancet, vol. 334, pp. 244-247.
Brennan, F.M. et al, 1996, “Cytokines in autoimmunity”,Curr. Opin. Immunol., vol. 8, pp. 872-877.
Brennan, F.M. et al, 1992, “Enhanced expression of tumor necrosis factor receptor mRNA and protein in mononuclear cells isolated from rheumatoid arthritis synovial joints”,Eur. J. Immunol., vol. 22, pp. 1907-1912.
Corey, E.J. et al, 1988, “An efficient and catalytically enantioselective route to (S)-(-)-Phenyloxirane,”J. Org. Chem., vol. 53, pp. 2861-2863.
Elliott, M.J. et al, 1994, “Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis”,Lancet, vol. 344, pp. 1105-1110.
Feldmann, M. et al, 1994, “TNF alpha as a therapeutic target in rheumatoid arthritis,”Circ. Shock, vol. 43, pp. 179-184.
Feldmann, M. et al, 2001, “The role of TNF alpha and IL-1 in rheumatoid arthritis,”Curr. Dir. Autoimmun., vol. 3, pp. 188-199.
Feldmann, M. et al, 1996, “Rheumatoid arthritis”,Cell, vol. 85, pp. 307-310.
Firestein, G.S. et al, 1996, “Invasive fibroblast-like synoviocytes in rheumatoid arthtitis. Passive responders or transformed aggressors?”,Arthritis Rheum., vol. 39, pp. 1781-1790.
Firestein, G.S. et al, 2005, “Immunologic mechanisms in the pathogenesis of rheumatoid arthritis”,J. Clin. Rheumatol., vol. 11. pp. S39-S44.
Firestein, G.S. et al, 1999, “Signal transduction and transcription factors in rheumatic disease”,Arthritis Rheum., vol. 42, pp. 609-621.
Gottlieb, A.B., 2005, “Psoriasis: Emerging Therapeutic Strategies”,Nat. Rev. Drug Disc., vol. 4, pp. 19-34.
“Chapter 4: Protection for the Carbonyl Group”, pp. 293-368 inProtective Groups in Organic Synthesis, Third Edition (Green, T.W. and Wuts, P.G.M., editors) (John Wiley & Sons, Inc., 1999).
Jimi, E. et al, 2004, “Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo”,Nat. Med., vol. 10, pp. 617-624.
Joosten, L.A. et al, 1996, “Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra,”Arthritis Rheum., vol. 39, pp. 797-809.
Klareskog, L. et al, 2006, “A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs”,Ann. Rheum. Dis., vol. 65, pp. 1578-1584.
Klareskog, L. et al, 2006, “Mechanisms of disease: Genetic susceptibility and environmental triggers in the development of rheumatoid arthritis,”Nat. Clin. Pract. Rheumatol., vol. 2, pp. 425-433.
Korzenik, J.R. et al, 2006, “Evolving knowledge and therapy of inflammatory bowel disease,”Nat. Rev. Drug Disc., vol. 5, pp. 197-209.
Liu, Z.G., 2005, “Molecular mechanism of TNF signaling and beyond,”Cell Res., vol. 15, pp. 24-27.
McInnes, I.B. et al, 2005, “Targeting cytokines beyond tumor necrosis factor-alpha and interleukin-1 in rheumatoid arthritis”,Curr. Pain Headache Rep., vol. 9, pp. 405-411.
Mount, C. et al, 2005, “Rheumatoid arthritis market”,Nat. Rev. Drug Disc., vol. 4, pp. 11-12.
Ramachandran, P.V. et al, 1995, “Chiral synthesis via organoboranes. 40. Selective reductions. 55. A simple on-pot synthesis of the enantiomers of (trifluoromethyl)oxirane. A general synthesis in high optical purities of alpha trifluoromethyl secondary alcohols via the ring-cleavage reactions of the epoxide”,J. Org. Chem., vol. 60, pp. 41-46.
Roodman, G.D., 2006, “Regulation of osteoclast differentiation”,Ann. N. Y. Acad. Sci., vol. 1068, pp. 100-109.
Smolen, J.S. et al, 2003, “Therapeutic Strategies for Rheumatoid Arthritis”,Nat. Rev. Drug Disc., vol. 2, pp. 473-488.
Tanaka, S. et al, 2003, “Signal transduction pathways regulating osteoclast differentiation and function,”J. Bone Miner. Metab., vol. 21, pp. 123-133.
Ueno, K., et al., 1969, “A new synthesis of Vitamin B6group”,Tetrahedron Letters, No. 16, pp. 1283-1286.
van den Berg, W.B., 2002, “Is there a rationale for combined TNF and IL-1 blocking in arthritis?”,Clin. Exp. Rheumatol., vol. 20, pp. S21-S25.
van den Berg, W.B. et al, 1999, “Pathogenesis of joint damage in rheumatoid arthritis: evidence of a dominant role for interleukin-I”,Baillieres Best Pract. Res. Clin. Rheumatol., vol. 13, pp. 577-597.
Weissmann, G., 2006, “The pathogenesis of rheumatoid arthritis,”Bull. Hosp. Jt. Dis., vol. 64, pp. 12-15.
Ziff, M., 1990, “Rheumatoid arthritis—it's present and future”,J. Rheumatol., vol. 17, pp. 127-133.
Armour K.J., et al., 2001, “Inhibition of bone resorption in vitro and prevention of ovariectomy-induced bone loss in vivo by flurbiprofen nitroxybutylester (HCT1026),”Arthritis and Rheumatism, vol. 44, No. 9, pp. 2185-2192.
Boots, M.R., et al., 1973, “Hypocholesterolemic Agents II: Inhibition of β-Hydroxy-β-Methylglutaryl Coenzyme A Reductase by Arylalkyl Hydrogen Succinates and Glutarates”,J. Pharm. Sci., vol. 62, No. 6, pp. 952-957.
Boots, M.R., et al, 1976, “Hypocholesterolemic Agents IV: Inhibition of β-Hydroxy-β- Methylglutaryl Coenzyme A Reductase by Arylalkenyl and Arylepoxy Hydrogen Succinates and Glutarates”,J. Pharm. Sci., vol. 65, No. 5, pp. 724-727.
Coxon, F.P., et al., 2000, “Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298,”J.Bone Miner.Res., vol. 15, pp. 1467-1476.
Degenhardt, C.R., et al., 1986, “Synthesis of Ethenylidenebis(phosphonic acid) and its Tetraalkyl Esters,”J. Org. Chem., vol. 51, pp. 3488-3490.
Eberhard, A., et al., 1965, “Hydrolysis of Phostonates,”J. Amer. Chem. Soc., vol. 87, pp. 253-260.
Herczegh, P., et al, 2002, “Osteoadsorptive Bisphosphonate Derivatives of Fluoroquinolone Antibacterials,”J. Med. Chem., vol. 45, pp. 2338-2341.
Hughes, D.E
Greig Iain R.
Mohamed Aymen I. I.
Ralston Stuart H.
Van 'T Hof Robert J.
Henley, III Raymond J
Nixon & Vanderhye P.C.
The University Court of the University of Aberdeen
LandOfFree
Ketones and reduced ketones as therapeutic agents for the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ketones and reduced ketones as therapeutic agents for the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ketones and reduced ketones as therapeutic agents for the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4068173